Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas
Authors:
- Hanna EngqvistHEHanna Engqvist
- Toshima Z. ParrisTPToshima Z. Parris
- Anikó KovácsAKAnikó Kovács
- Szilárd NemesSNSzilárd Nemes
- Elisabeth Werner RönnermanERElisabeth Werner Rönnerman
- Shahin De LaraSLShahin De Lara
- Jana BiermannJBJana Biermann
- Karin SundfeldtKSKarin Sundfeldt
- Per KarlssonPKPer Karlsson
- Khalil HelouKhalil Helou
Open Access
- 18 September 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-12
Abstract
Background: Ovarian cancer is the main cause of gynecological cancer-associated death. However, 5-year survival rates differ dramatically between the five main ovarian carcinoma histotypes. Therefore, we need to have a better understanding of the mechanisms that promote histotype-specific ovarian carcinogenesis and identify novel prognostic biomarkers. Methods: Here, we evaluated the prognostic role of 29 genes for early-stage (I and II) ovarian carcinomas (n = 206) using immunohistochemistry (IHC). Results: We provide evidence of aberrant protein expression patterns for Collagen type III alpha 1 chain (COL3A1), G protein-coupled receptor 158 (GPR158) and PITH domain containing 1 (PITHD1). Kaplan-Meier survival analysis revealed that COL3A1 expression was associated with shorter overall survival in the four major histotypes of epithelial ovarian carcinoma patients (P value = 0.026, HR = 2.99 (95% CI 1.089–8.19)). Furthermore, GPR158 and PITHD1 were shown to be histotype-specific prognostic biomarkers, with elevated GPR158 expression patterns in mucinous ovarian carcinoma patients with unfavorable overall survival (P value = 0.00043, HR = 6.13 (95% CI 1.98–18.98)), and an association with lower PITHD1 protein expression and unfavorable overall and disease-specific survival in clear-cell ovarian carcinoma patients (P value = 0.012, HR = 0.22 (95% CI 0.058–0.80); P value = 0.003, HR = 0.17 (95% CI 0.043–0.64)). Conclusions: The novel biomarkers identified here may improve prognostication at the time of diagnosis and may assist in the development of future individualized therapeutic strategies for ovarian carcinoma patients.Keywords
Funding Information
- Cancerfonden (CAN 2018/417)
- Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer (2017:144)
- Stiftelsen Assar Gabrielssons Fond (FB 17-08, FB 18-69)
This publication has 44 references indexed in Scilit:
- Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen depositionBMC Cancer, 2014
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and ElaborationPLOS Medicine, 2012
- Insights into the regulation of protein abundance from proteomic and transcriptomic analysesNature Reviews Genetics, 2012
- Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological featuresVirchows Archiv, 2012
- Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patientsEndocrine-Related Cancer, 2012
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- Discrepancy between mRNA and protein abundance: Insight from information retrieval process in computersComputational Biology and Chemistry, 2008
- Crosstalk between G-protein-coupled receptors and Epidermal growth factor receptor in cancerFrontiers in Bioscience-Landmark, 2008
- CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patientsGynecologic Oncology, 2007
- Specificity and Affinity of 26 Monoclonal Antibodies against the CA 125 Antigen: First Report from the ISOBM TD-1 WorkshopTumor Biology, 1996